Grade @/@ adverse events were @ % versus @ % ( P = @ ) ; the most frequent G@/@ toxicities were vomiting ( @ % saracatinib versus @ % placebo ) , abdominal pain ( @ % versus @ % ) and diarrhoea ( @ % versus @ % ) .